A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability, and efficacy of mivavotinib in patients with refractory a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratz, Keith W., Kaplan, Jason, Levy, Moshe, Bixby, Dale, Burke, Patrick W., Erba, Harry, Wise-Draper, Trisha M., Roboz, Gail J., Papadantonakis, Nikolaos, Rajkhowa, Trivikram, Hernandez, Daniela, Dobler, Iwona, Gregory, Richard C., Li, Cheryl, Wang, Shining, Stumpo, Kate, Kannan, Karuppiah, Miao, Harry, Levis, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973464/
https://www.ncbi.nlm.nih.gov/pubmed/36226495
http://dx.doi.org/10.3324/haematol.2022.281216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973464/
https://www.ncbi.nlm.nih.gov/pubmed/36226495
http://dx.doi.org/10.3324/haematol.2022.281216

Ejemplares similares